stockrow
Friday 6 November 2026
Export RDY’s income statement to Excel — free account
Dr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
14.86
0.33
+2.27%
Follow RDY
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | 6 |
| 16.28% | 11.40% | 8.21% | 6.60% | ||
| 10.88% | 7.63% | 5.55% | 4.44% | ||
ROIC |
11.88% | 8.55% | 5.89% | 4.77% | |
Return on Tangible Assets |
22.80% | 17.09% | 12.38% | 9.98% | |
Average Days of Receivables |
106.53 | 110.01 | 112.81 | 115.83 | |
Free Cash Flow per Share |
0.35 | 0.26 | 0.18 | 0.12 | |
Free Cash Flow |
288.00 | 215.00 | 139.00 | 96.00 | |
Capital Expenditures |
(429.00) | (392.00) | (287.00) | (217.00) | |
| Other line items | |||||
Cash ROIC |
4.91% | 3.70% | 2.43% | 1.71% | |
Accounts Receivable Turnover |
3.54 | 3.35 | 3.16 | 3.09 | |
Accounts Payable Turnover |
4.03 | 4.38 | 4.12 | 4.08 | |
Inventory Turnover |
2.06 | 2.05 | 1.98 | 1.99 | |
Average Days of Payables |
93.93 | 76.84 | 84.13 | 81.19 | |
Days of Inventory on Hand |
181.86 | 176.13 | 180.59 | 182.41 | |
Tax Rate |
(0.23) | (0.23) | (0.21) | (0.21) | |
Research and Development Expense of Revenue |
7.47% | 7.15% | 7.10% | 6.83% | |
Selling, General and Administrative Expense of Revenue |
29.80% | 31.76% | 33.24% | 33.98% | |
Share Based Compensation of Revenue |
0.10% | 0.08% | 0.09% | 0.09% | |
Interest Coverage |
19.90 | 13.48 | 8.52 | 6.57 | |
Operating CF/Net income |
1.11 | 1.33 | 1.26 | 1.16 | |
Depreciation/Fixed assets |
0.17 | 0.18 | 0.18 | 0.18 | |
Capex/Depreciation |
(1.94) | (1.78) | (1.30) | (0.99) | |
Revenue per Share |
4.73 | 4.30 | 4.39 | 4.00 | |
Operating CF per Share |
0.86 | 0.73 | 0.54 | 0.38 | |
Capex per Share |
(0.52) | (0.47) | (0.37) | (0.26) | |
Capex to Sales |
0.11 | 0.11 | 0.08 | 0.07 |
Columns are period end dates · fundamentals updated 2 Nov 2026